摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-{[(2RS)-3-amino-2-hydroxypropyl]oxy}phenyl)acetamide | 41865-62-7

中文名称
——
中文别名
——
英文名称
N-(4-{[(2RS)-3-amino-2-hydroxypropyl]oxy}phenyl)acetamide
英文别名
1-(4-acetamidophenoxy)-3-aminopropan-2-ol;3-(4-acetylamidophenoxy)-2-hydroxypropylamine;1-(4-acetamino-phenoxy)-3-amino-propan-2-ol;1-(4-acetamidophenoxy)-3-amino propan-2-ol;1-Amino-3-(4'-acetamidophenoxy)-2-propanol;N-[4-(3-amino-2-hydroxypropoxy)phenyl]acetamide
N-(4-{[(2RS)-3-amino-2-hydroxypropyl]oxy}phenyl)acetamide化学式
CAS
41865-62-7
化学式
C11H16N2O3
mdl
MFCD00157551
分子量
224.26
InChiKey
RQWDNMOAQIUREU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    505.9±45.0 °C(Predicted)
  • 密度:
    1.238±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.363
  • 拓扑面积:
    84.6
  • 氢给体数:
    3
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-(4-{[(2RS)-3-amino-2-hydroxypropyl]oxy}phenyl)acetamide咪唑 作用下, 以 四氢呋喃乙腈 为溶剂, 反应 18.17h, 生成
    参考文献:
    名称:
    新型高度官能化胍的构建方法
    摘要:
    在这项研究中,我们提出了一种针对高度功能化胍的快速化学选择性方案。在氢氧化铵的存在下,通过环氧化物的区域选择性开环,在微波中构建含有羟基官能团的胍,得到伯胺,然后与异硫脲盐反应。在正丁基锂的存在下,未取代的胍与环氧化物的直接偶联得到相同的产物。
    DOI:
    10.1055/s-2004-829561
  • 作为产物:
    描述:
    N-[4-(3-Benzylamino-2-hydroxy-propoxy)-phenyl]-acetamide; hydrochloride 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 生成 N-(4-{[(2RS)-3-amino-2-hydroxypropyl]oxy}phenyl)acetamide
    参考文献:
    名称:
    Trichloroacetamidines, a new class of positive inotropic agents
    摘要:
    A series of trichloroacetamidine derivatives, obtained by addition of amines to trichloroacetonitrile, was evaluated for positive inotropic activity on isolated cat heart papillary muscles. Increased contractility, not antagonized by beta-adrenergic blockade with sotalol or reserpine pretreatment, was observed in this assay with a variety of N-substituted trichloroacetamidine derivatives. More extensive pharmacological studies with the 3-indolylmethyl analogue 2 showed that this amidine in dogs, 5 mg/kg iv, produced a positive inotropic effect more pronounced than that of ouabain, 50 microgram/kg iv. Several of the trichloroacetamidines were found to be inhibitors of guinea pig kidney and calf heart Na-K-dependent ATPase and to have specificity for these enzymes different from that of ouabain. Bacterial mutagenic activity was observed with three members, 2,3, and 12, of the series.
    DOI:
    10.1021/jm00210a021
点击查看最新优质反应信息

文献信息

  • Pharmaceutically active pyrrolidine derivatives as bax inhibitors
    申请人:——
    公开号:US20030171309A1
    公开(公告)日:2003-09-11
    The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR<6>R<7>, NOR<6>, NNR<6>R<7>; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NR<8>R<9> or represents a heterocyclic residue having the formula (II) wherein Q is NR<10>, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.
    本发明涉及新的取代吡咯烷衍生物的化学式(I)。所述化合物通常用作药用活性化合物。具体来说,化学式(I)的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用处。所述吡咯烷衍生物显示出对细胞死亡促进子Bax和/或导致Bax激活途径的调节作用,最显著地是下调至抑制活性,并因此允许阻止细胞色素(c)的释放。本发明还涉及新的具有药用活性的取代吡咯烷衍生物,以及它们的制备方法,其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群;A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2-、—SO2NH—;—CH2-;B是一个群—(C═O)—NR<8>R<9>或代表具有化学式(II)的杂环残基,其中Q是NR<10>、O或S;n是选自0、1或2的整数;Y、Z和E与它们连接的两个碳共同形成一个5-6成员芳香族或杂芳族环。
  • Pharmaceutically active pyrrolidine derivatives
    申请人:——
    公开号:US20030212012A1
    公开(公告)日:2003-11-13
    The present invention is related to pyrrolidine derivatives of formula (I). Said 1 compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.
    本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言,式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是,本发明涉及显示出氧催产素受体显著调节作用,特别是拮抗剂活性的吡咯烷衍生物。更具体地,所述化合物在治疗和/或预防由氧催产素介导的疾病状态,包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法,其中X从CR6R7、NOR6、NNR6R7组中选择;A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择;B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基,其中Q是NR10、O或S;n是选择的整数0、1或2;Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
  • Phenoxypropanolamine therapeutic agents
    申请人:Pfizer Inc.
    公开号:US03961072A1
    公开(公告)日:1976-06-01
    A series of novel substituted phenoxypropylamine derivatives have been prepared by reacting the appropriate 1-phenoxy-2,3-epoxypropane compound with a suitable organic amine reagent. The resulting 1-phenoxy-3-alkylaminopropan-2-ols are useful in the field of chemotherapy as anti-angina agents. Preferred members include compounds having an acetamido group substituted on the phenyl ring of the phenoxy moiety. Alternate methods of preparation are also provided.
    一系列新型的取代苯氧丙胺衍生物已经通过将适当的1-苯氧基-2,3-环氧丙烷化合物与适当的有机胺试剂反应而制备出来。所得的1-苯氧基-3-烷基氨丙醇在化疗领域中作为抗心绞痛剂是有用的。首选成员包括在苯氧基部分的苯环上取代有乙酰胺基团的化合物。另外提供了其他制备方法。
  • [EN] N-ARYLOXYPROPANOLYL-N'-PHENETHYL-UREA<br/>[FR] N-ARYLOXYPROPANOLYL-N'-PHENETHYL-UREE
    申请人:COUNCIL SCIENT IND RES
    公开号:WO2005063699A1
    公开(公告)日:2005-07-14
    The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected from the group consisting of H, 2, 3, or 4-trifluoromethyl, 2, 3, or 4-chloro, 2, 3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2, 3 or 4 methoxy, 4 nitrile, 2, 3 or 4-methyl, and 4 formyl and X is S or O.
    本发明提供了式(3)的N-芳氧基丙酰基-N'-苯乙基脲衍生物,其制备方法以及作为治疗肥胖症的有效食欲抑制剂的用途。式(3):其中R选自H,2,3或4-三氟甲基,2,3或4-氯,2,3或4-溴,4-乙酰基,4-丙酰基,4-乙酰胺基,2,3或4-甲氧基,4-腈基,2,3或4-甲基和4-甲酰基的群,X为S或O。
  • NOVEL N-ARYLOXYPROPANOLYL-N' - PHENETHYL - UREA
    申请人:Bhandari Kalpana
    公开号:US20050215631A1
    公开(公告)日:2005-09-29
    The present invention provides N-aryloxypropanolyl-N′-phenethyl-urea derivatives of formula 3, method for their preparation and use thereof as potent appetite suppressants for treatment of obesity wherein R is selected from the group consisting of H, 2, 3 or 4-trifluoromethyl, 2, 3, or 4-chloro, 2, 3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2, 3 or 4 methoxy, 4 nitrile, 2, 3 or 4-methyl, and 4 formyl and X is S or O.
    本发明提供了公式3的N-芳氧基丙酰基-N'-苯乙基脲衍生物,其制备方法以及作为治疗肥胖症的有效食欲抑制剂的用途,其中R从H,2,3或4-三氟甲基,2,3或4-氯,2,3或4-溴,4-乙酰基,4-丙酰基,4-乙酰胺基,2,3或4-甲氧基,4-腈基,2,3或4-甲基和4-甲酰基的群中选择,X为S或O。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐